The data presented in this study along with previous work in Nigeria suggests that the use of PN 3.0 will contribute towards a reduction in malaria transmission over time when compared to existing pyrethroid-only LLINs in areas with P450-based pyrethroid metabolic resistance. This evidence concerns the gene CYP2B6 and malaria.